FINWIRES · TerminalLIVE
FINWIRES

UAE Shares Diverge as Oil Prices Rise Amid Uncertainty Over US-Iran Conflict

By

-- Emirati shares struggled to find direction on Tuesday as continued uncertainty over the reopening of the Strait of Hormuz drove oil prices up.

At the close of trading, the FTSE ADX General Index was little changed at 0.080% in the green, while the DFM General Index was down 0.218%.

According to reports from various media outlets, US President Donald Trump is not satisfied with Iran's new proposal, which consisted of reopening the Hormuz waterway and postponing negotiations over its nuclear program to a later stage.

"We doubt that the US will go for this, since the US's economic blockade of the Iran remains its key 'pressure tactic' in making Iran concede to the US's fundamental demands pertaining to Iran's power. Yet that it is Iran that is making the proposal suggests that the pressure from the US's economic blockade is being felt, and that the US may not need to invoke its military power again," Macquarie said in a note. " To the US administration, the economic blockade of Iran is intended to have that very effect, i.e., of causing revenue losses that lead to monetary inflation and, ultimately, instability within the regime, and leading to concessions from Iran on the fundamental issues that the US has raised."

As of 3:51 pm UAE time, the Brent crude oil futures stood at nearly $112.374 per barrel, up 3.81% from the previous day.

Back home, the local economic calendar will see the release of the interest rate decision from the Central Bank of the United Arab Emirates later in the week, following the US Federal Reserve's verdict on its federal funds rate on Wednesday.

In corporate news, Aldar Properties (ADX:ALDAR) released its first-quarter earnings report. The real estate developer reported a 12% annual growth in its revenue but closed the trading session 0.37% in the red.

Elsewhere, shares of Dubai Investments (DFM:DIC) lost 0.97%. The Dubai-listed investment company declared plans to sell a 24% stake in its unit, Dubai Investments Park, through an initial public offering and distribute improved dividends in 2026, subject to completion of the offering.

Related Articles

Sectors

Sector Update: Tech Stocks Fall Late Afternoon

Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.

$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research

Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.

$PCAR
Australia

Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data

Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%

$ERAS